Cargando…

Avidity of anti-phospholipid antibodies in relation to their levels

INTRODUCTION: The heterogeneity of anti-phospholipid antibodies can be manifested not only in different antigenic specificities, but also in their avidities. The aim of the study was to investigate the relationship between anti-cardiolipin antibody (aCL) IgG avidities and levels within the range of...

Descripción completa

Detalles Bibliográficos
Autores principales: FIALOVÁ, LENKA, KUCHAŘ, OLIVER, PETRÁČKOVÁ, MILADA, MALBOHAN, IVAN, ZIMA, TOMÁŠ
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792445/
https://www.ncbi.nlm.nih.gov/pubmed/33456323
http://dx.doi.org/10.5114/ceji.2020.97901
_version_ 1783633807848505344
author FIALOVÁ, LENKA
KUCHAŘ, OLIVER
PETRÁČKOVÁ, MILADA
MALBOHAN, IVAN
ZIMA, TOMÁŠ
author_facet FIALOVÁ, LENKA
KUCHAŘ, OLIVER
PETRÁČKOVÁ, MILADA
MALBOHAN, IVAN
ZIMA, TOMÁŠ
author_sort FIALOVÁ, LENKA
collection PubMed
description INTRODUCTION: The heterogeneity of anti-phospholipid antibodies can be manifested not only in different antigenic specificities, but also in their avidities. The aim of the study was to investigate the relationship between anti-cardiolipin antibody (aCL) IgG avidities and levels within the range of their titres, from very low to high ones. MATERIAL AND METHODS: We analyzed 78 serum samples from 60 patients by ELISA with chaotropic agents, using urea concentration of 6 and 8 mol/l and single diluted serum samples. The changes of aCL levels and avidities were explored during a long-term follow-up in 14 patients. RESULTS: The avidities of aCLs did not differ in the groups of patients classified according to aCL levels. The higher avidity antibodies predominated in our patients and the fluctuation of avidities in the longitudinal follow-up did not show significant differences. No relationship between aCL levels and their avidities was found. CONCLUSIONS: aCL avidities seem to have no relationship with aCL levels and high-avidity aCLs; the potentially deleterious effects might be present also in patients with low and extremely low aCL levels. Avidity of aCLs belongs to stable characteristics with insignificant changes in time.
format Online
Article
Text
id pubmed-7792445
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-77924452021-01-15 Avidity of anti-phospholipid antibodies in relation to their levels FIALOVÁ, LENKA KUCHAŘ, OLIVER PETRÁČKOVÁ, MILADA MALBOHAN, IVAN ZIMA, TOMÁŠ Cent Eur J Immunol Clinical Immunology INTRODUCTION: The heterogeneity of anti-phospholipid antibodies can be manifested not only in different antigenic specificities, but also in their avidities. The aim of the study was to investigate the relationship between anti-cardiolipin antibody (aCL) IgG avidities and levels within the range of their titres, from very low to high ones. MATERIAL AND METHODS: We analyzed 78 serum samples from 60 patients by ELISA with chaotropic agents, using urea concentration of 6 and 8 mol/l and single diluted serum samples. The changes of aCL levels and avidities were explored during a long-term follow-up in 14 patients. RESULTS: The avidities of aCLs did not differ in the groups of patients classified according to aCL levels. The higher avidity antibodies predominated in our patients and the fluctuation of avidities in the longitudinal follow-up did not show significant differences. No relationship between aCL levels and their avidities was found. CONCLUSIONS: aCL avidities seem to have no relationship with aCL levels and high-avidity aCLs; the potentially deleterious effects might be present also in patients with low and extremely low aCL levels. Avidity of aCLs belongs to stable characteristics with insignificant changes in time. Termedia Publishing House 2020-07-27 2020 /pmc/articles/PMC7792445/ /pubmed/33456323 http://dx.doi.org/10.5114/ceji.2020.97901 Text en Copyright © 2020 Termedia http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/)
spellingShingle Clinical Immunology
FIALOVÁ, LENKA
KUCHAŘ, OLIVER
PETRÁČKOVÁ, MILADA
MALBOHAN, IVAN
ZIMA, TOMÁŠ
Avidity of anti-phospholipid antibodies in relation to their levels
title Avidity of anti-phospholipid antibodies in relation to their levels
title_full Avidity of anti-phospholipid antibodies in relation to their levels
title_fullStr Avidity of anti-phospholipid antibodies in relation to their levels
title_full_unstemmed Avidity of anti-phospholipid antibodies in relation to their levels
title_short Avidity of anti-phospholipid antibodies in relation to their levels
title_sort avidity of anti-phospholipid antibodies in relation to their levels
topic Clinical Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792445/
https://www.ncbi.nlm.nih.gov/pubmed/33456323
http://dx.doi.org/10.5114/ceji.2020.97901
work_keys_str_mv AT fialovalenka avidityofantiphospholipidantibodiesinrelationtotheirlevels
AT kucharoliver avidityofantiphospholipidantibodiesinrelationtotheirlevels
AT petrackovamilada avidityofantiphospholipidantibodiesinrelationtotheirlevels
AT malbohanivan avidityofantiphospholipidantibodiesinrelationtotheirlevels
AT zimatomas avidityofantiphospholipidantibodiesinrelationtotheirlevels